Edoxaban Versus Dalteparin in Cancer-Associated VTE – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Nick van Es et al, adding:
”The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE Cancer trial
Novel win ratio analysis comparing edoxaban versus dalteparin in cancer-associated VTE reveals no significant difference between treatments when evaluating hierarchically prioritized outcomes including mortality, recurrent events, and bleeding complications.”
Title: The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial
Authors: Nick van Es, Luuk Scheres., Kristen Sanfilippo, Harry Buller, Marc Carrier, Marcello Di Nisio, Michael A. Grosso, Renato D. Lopes, William McIntyre, Björn Redfors, Annelise Segers, Peter Verhamme, Jeff Weitz, Patrick Bossuyt, Deborah Siegal
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 30, 2026, 13:03Amira Mohy: Diagnostic Flow Cytometry Panels for Hematological Malignancies
-
Sep 30, 2026, 12:52Paul Watton: Could Repetitive Head Impacts Leave a Molecular Memory?
-
Sep 30, 2026, 12:41The Journey to ISTH 2027 Starts in Vancouver
-
Sep 30, 2026, 11:36Basit Ali: A Closer Look at CT Venography
-
Sep 30, 2026, 11:16Christina Pohlman: Could aPL Levels Help Predict Stroke Recurrence?
-
Sep 30, 2026, 10:55Rana Al Hrout: Diagnostic Approach to Hypochromic Microcytic Anemia
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate